Previous studies have indicated that RRM2 promotes cell proliferation, migration and angiogenesis through the PI3K/AKT pathway and that targeting RRM2 in NSCLC and breast cancer inhibits these processes by reducing PI3K/AKT expression at both the mRNA and protein levels (Han et al. 2021; Zhuang et al. 2020). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.